M. Offidani and L. Corvatta, “Elotuzumab: the first available immunotherapeutic arrow against relapsed-refractory Multiple Myeloma”, Eur J Oncol Env Hea, vol. 22, no. 2, pp. 65–70, Nov. 2017, Accessed: Jan. 25, 2025. [Online]. Available: https://mail.mattioli1885journals.com/index.php/EJOEH/article/view/6857